Search

Your search keyword '"Goodwin, Guy"' showing total 673 results
Start Over Author "Goodwin, Guy" Publication Year Range Last 10 years
673 results on '"Goodwin, Guy"'

1. The True Colours Remote Symptom Monitoring System: A Decade of Evolution

Author

Goodday, Sarah M, Atkinson, Lauren, Goodwin, Guy, Saunders, Kate, South, Matthew, Mackay, Clare, Denis, Mike, Hinds, Chris, Attenburrow, Mary-Jane, Davies, Jim, Welch, James, Stevens, William, Mansfield, Karen, Suvilehto, Juulia, and Geddes, John

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

The True Colours remote mood monitoring system was developed over a decade ago by researchers, psychiatrists, and software engineers at the University of Oxford to allow patients to report on a range of symptoms via text messages, Web interfaces, or mobile phone apps. The system has evolved to encompass a wide range of measures, including psychiatric symptoms, quality of life, and medication. Patients are prompted to provide data according to an agreed personal schedule: weekly, daily, or at specific times during the day. The system has been applied across a number of different populations, for the reporting of mood, anxiety, substance use, eating and personality disorders, psychosis, self-harm, and inflammatory bowel disease, and it has shown good compliance. Over the past decade, there have been over 36,000 registered True Colours patients and participants in the United Kingdom, with more than 20 deployments of the system supporting clinical service and research delivery. The system has been adopted for routine clinical care in mental health services, supporting more than 3000 adult patients in secondary care, and 27,263 adolescent patients are currently registered within Oxfordshire and Buckinghamshire. The system has also proven to be an invaluable scientific resource as a platform for research into mood instability and as an electronic outcome measure in randomized controlled trials. This paper aimed to report on the existing applications of the system, setting out lessons learned, and to discuss the implications for tailored symptom monitoring, as well as the barriers to implementation at a larger scale.

Published
2020
Full Text
View/download PDF

2. Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Author

Pasculli, Giuseppe, Busan, Pierpaolo, Jackson, Eric, Alm, Per, De Gregorio, Danilo, Maguire, Gerald, Goodwin, Guy, Gobbi, Gabriella, Erritzoe, David, and Carhart-Harris, Robin

Subjects
default mode network, developmental stuttering, neuropsychopharmacology, psychedelic compounds, social-cognitive networks
Abstract

Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies- arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS. The neural background of DS is likely to be heterogeneous, and some contribution from genetically determinants of metabolic deficiencies in the basal ganglia and speech-motor cortical regions are thought to play a role in appearance of DS symptoms, which possibly results in a cascade of events contributing to impairments in speech-motor execution. In persistent DS, the difficulties of speech are often linked to a series of associated aspects such as social anxiety and social avoidance. In this context, the SCN and DMN (also influencing a series of fronto-parietal, somato-motor, and attentional networks) may have a role in worsening dysfluencies. Interestingly, brain metabolism and SCN/DMN connectivity can be modified by psychedelics, which have been shown to improve clinical evidence of some psychiatric conditions (e.g., depression, post-traumatic stress disorder, etc.) associated with psychological constructs such as rumination and social anxiety, which also tend to be present in persistent DS. To date, while there have been no controlled trials on the effects of psychedelics in DS, anecdotal evidence suggests that these agents may have beneficial effects on stuttering and its associated characteristics. We suggest that psychedelics warrant investigation in DS.

Published
2024

3. Neuroscience-Based Nomenclature (NbN): A New Pharmacological Driven Classification of Psychotropics

Author

Levy, Daniel Minkin, Zemach, Sasson, Goodwin, Guy M., Pato, Michele T., Zohar, Joseph, Kanba, Shigenobu, Section editor, El-Mallakh, Rif S., Section editor, Krystal, Andrew D., Section editor, Tasman, Allan, editor, Riba, Michelle B., editor, Alarcón, Renato D., editor, Alfonso, César A., editor, Kanba, Shigenobu, editor, Lecic-Tosevski, Dusica, editor, Ndetei, David M., editor, Ng, Chee H., editor, and Schulze, Thomas G., editor

Published
2024
Full Text
View/download PDF

7. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression

Author

Jauhar, Sameer, Arnone, Danilo, Baldwin, David S., Bloomfield, Michael, Browning, Michael, Cleare, Anthony J., Corlett, Phillip, Deakin, J. F. William, Erritzoe, David, Fu, Cynthia, Fusar-Poli, Paolo, Goodwin, Guy M., Hayes, Joseph, Howard, Robert, Howes, Oliver D., Juruena, Mario F., Lam, Raymond W., Lawrie, Stephen M., McAllister-Williams, Hamish, Marwaha, Steven, Matuskey, David, McCutcheon, Robert A., Nutt, David J., Pariante, Carmine, Pillinger, Toby, Radhakrishnan, Rajiv, Rucker, James, Selvaraj, Sudhakar, Stokes, Paul, Upthegrove, Rachel, Yalin, Nefize, Yatham, Lakshmi, Young, Allan H., Zahn, Roland, and Cowen, Philip J.

Published
2023
Full Text
View/download PDF

9. Monitoring Depression in Bipolar Disorder using Circadian Measures from Smartphone Accelerometers

Author

Carr, Oliver, Andreotti, Fernando, Saunders, Kate E. A., Palmius, Niclas, Goodwin, Guy M., and De Vos, Maarten

Subjects
Electrical Engineering and Systems Science - Signal Processing, Computer Science - Human-Computer Interaction
Abstract

Current management of bipolar disorder relies on self-reported questionnaires and interviews with clinicians. The development of objective measures of deteriorating mood may also allow for early interventions to take place to avoid transitions into depressive states. The objective of this study was to use acceleration data recorded from smartphones to predict levels of depression in a population of participants diagnosed with bipolar disorder. Data were collected from 52 participants, with a mean of 37 weeks of acceleration data with a corresponding depression score recorded per participant. Time varying hidden Markov models were used to extract weekly features of activity, sleep and circadian rhythms. Personalised regression achieved mean absolute errors of 1.00(0.57) from a possible scale of 0 to 27 and was able to classify depression with an accuracy of 0.84(0.16). The results demonstrate features derived from smartphone accelerometers are able to provide objective markers of depression. Low barriers for uptake exist due to the widespread use of smartphones, with personalised models able to account for differences in the behaviour of individuals and provide accurate predictions of depression., Comment: 8 pages, 3 figures

Published
2020

14. Combining antidepressants and attention bias modification in primary health care (DEPTREAT): Protocol for a pragmatic randomized controlled trial

Author

Landrø, Nils Inge, Harmer, Catherine J., Blackwell, Simon E., Bø, Ragnhild, Dawson, Gerry, Goodwin, Guy, Hagen, Hallvard Solbø, Kingslake, Jonathan, Klovning, Atle, Klungsøyr, Ole, Schjøtt-Pedersen, Olivia, Sæther, Anne Kjersti, Torgersen, Kristin Stensland, Vaaler, Arne, Andreassen, Ole A., and Røssberg, Jan Ivar

Published
2023
Full Text
View/download PDF

17. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Author

Goodwin, Guy M., Aaronson, Scott T., Alvarez, Oscar, Atli, Merve, Bennett, James C., Croal, Megan, DeBattista, Charles, Dunlop, Boadie W., Feifel, David, Hellerstein, David J., Husain, Muhammad Ishrat, Kelly, John R., Lennard-Jones, Molly R., Licht, Rasmus W., Marwood, Lindsey, Mistry, Sunil, Páleníček, Tomáš, Redjep, Ozlem, Repantis, Dimitris, Schoevers, Robert A., Septimus, Batya, Simmons, Hollie J., Soares, Jair C., Somers, Metten, Stansfield, Susan C., Stuart, Jessica R., Tadley, Hannah H., Thiara, Nisha K., Tsai, Joyce, Wahba, Mourad, Williams, Sam, Winzer, Rachel I., Young, Allan H., Young, Matthew B., Zisook, Sid, and Malievskaia, Ekaterina

Published
2023
Full Text
View/download PDF

19. Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs

Author

Similon, Miriam von Mücke, Paasche, Cecilia, Krol, Fas, Lerer, Bernard, Goodwin, Guy M., Berk, Michael, Meyer-Lindenberg, Andreas, Ketter, Terence A., Yatham, Lakshmi N., Goldberg, Joseph F., Malhi, Gin S., El-Mallakh, Rif, Licht, Rasmus W., Young, Allan H., Kapczinski, Flavio, Swartz, Marnina, Hagin, Michal, Torrent, Carla, Serretti, Alessandro, Yildiz, Ayşegül, Martínez-Arán, Anabel, Strejilevich, Sergio, Rybakowski, Janusz, Sani, Gabriele, Grunze, Heinz, Vázquez, Gustavo, Pinto, Ana Gonzales, Azorin, Jean Michel, Nolen, Willem, Sentissi, Othman, López-Jaramillo, Carlos, Frey, Benicio N., Nierenberg, Andrew, Parker, Gordon, Bond, David J, Cohen, Adam, Tortorella, Alfonso, Perugi, Giulio, Vieta, Eduard, and Popovic, Dina

Published
2022
Full Text
View/download PDF

20. Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.

Author

Kirlić, Namik, Lennard-Jones, Molly, Atli, Merve, Malievskaia, Ekaterina, Modlin, Nadav L., Peck, Stephanie Knatz, Gaillard, Alice, Goodwin, Guy M., and Koelpin, Don

Subjects
MENTAL health services, PSILOCYBIN, MENTAL depression, PSYCHOTHERAPY, CLINICAL trials
Abstract

The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy that most optimally complement psilocybin treatment. The authors describe the Compass Psychological Support Model (CPSM), currently used to support participants with treatment-resistant depression in Compass-sponsored clinical trials of investigational COMP360 psilocybin treatment. The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

21. A signature-based machine learning model for bipolar disorder and borderline personality disorder

Author

Arribas, Imanol Perez, Saunders, Kate, Goodwin, Guy, and Lyons, Terry

Subjects
Statistics - Machine Learning
Abstract

Mobile technologies offer opportunities for higher resolution monitoring of health conditions. This opportunity seems of particular promise in psychiatry where diagnoses often rely on retrospective and subjective recall of mood states. However, getting actionable information from these rather complex time series is challenging, and at present the implications for clinical care are largely hypothetical. This research demonstrates that, with well chosen cohorts (of bipolar disorder, borderline personality disorder, and control) and modern methods, it is possible to objectively learn to identify distinctive behaviour over short periods (20 reports) that effectively separate the cohorts. Participants with bipolar disorder or borderline personality disorder and healthy volunteers completed daily mood ratings using a bespoke smartphone app for up to a year. A signature-based machine learning model was used to classify participants on the basis of the interrelationship between the different mood items assessed and to predict subsequent mood. The signature methodology was significantly superior to earlier statistical approaches applied to this data in distinguishing the participant three groups, clearly placing 75% into their original groups on the basis of their reports. Subsequent mood ratings were correctly predicted with greater than 70% accuracy in all groups. Prediction of mood was most accurate in healthy volunteers (89-98%) compared to bipolar disorder (82-90%) and borderline personality disorder (70-78%).

Published
2017
Full Text
View/download PDF

22. Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review

Author

Reininghaus, Eva Z, Manchia, Mirko, Dalkner, Nina, Bonkat, Nina, Squassina, Alessio, Hodl, Isabel, Vieta, Eduard, Reif, Andreas, Hajek, Tomas, Landén, Mikael, Correll, Christoph U, Scott, Jan, Etain, Bruno, Rietschel, Marcella, Bergink, Veerle, Martinez-Cengotitabengoa, Monica, Kessing, Lars Vedel, Fagiolini, Andrea, Bauer, Michael, Goodwin, Guy, Gonzalez-Pinto, Ana, Kupka, Ralph W, Schulze, Thomas G, Lagerberg, Trine V, Yildiz, Ayşegül, Henry, Chantal, Morken, Gunnar, Ritter, Phillip, Nieslen, René Ernst, Licht, Rasmus W, Bechdolf, Andreas, Andreassen, Ole A, and Fellendorf, Frederike Tabea

Published
2022
Full Text
View/download PDF

25. DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis – A narrative review from the ECNP bipolar disorders network

Author

Kessing, Lars Vedel, González-Pinto, Ana, Fagiolini, Andrea, Bechdolf, Andreas, Reif, Andreas, Yildiz, Ayşegül, Etain, Bruno, Henry, Chantal, Severus, Emanuel, Reininghaus, Eva Z., Morken, Gunnar, Goodwin, Guy M., Scott, Jan, Geddes, John R., Rietschel, Marcella, Landén, Mikael, Manchia, Mirko, Bauer, Michael, Martinez-Cengotitabengoa, Monica, Andreassen, Ole A., Ritter, Philipp, Kupka, Ralph, Licht, Rasmus W., Nielsen, René Ernst, Schulze, Thomas G., Hajek, Tomas, Lagerberg, Trine Vik, Bergink, Veerle, and Vieta, Eduard

Published
2021
Full Text
View/download PDF

26. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Author

Carhart-Harris, Robin L and Goodwin, Guy M

Subjects
Mental Health, Brain Disorders, Depression, Mental health, Good Health and Well Being, Animals, Hallucinogens, History, 20th Century, History, 21st Century, Humans, Mental Disorders, Psilocybin, Medical and Health Sciences, Psychology and Cognitive Sciences, Psychiatry
Abstract

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

Published
2017

31. The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial

Author

Browning, Michael, Bilderbeck, Amy C., Dias, Rebecca, Dourish, Colin T., Kingslake, Jonathan, Deckert, Jürgen, Goodwin, Guy M., Gorwood, Philip, Guo, Boliang, Harmer, Catherine J., Morriss, Richard, Reif, Andreas, Ruhe, Henricus G., van Schaik, Anneke, Simon, Judit, Sola, Victor Perez, Veltman, Dick J., Elices, Matilde, Lever, Anne G., Menke, Andreas, Scanferla, Elisabetta, Stäblein, Michael, and Dawson, Gerard R.

Published
2021
Full Text
View/download PDF

33. Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

Author

Manchia, Mirko, Vieta, Eduard, Smeland, Olav B., Altimus, Cara, Bechdolf, Andreas, Bellivier, Frank, Bergink, Veerle, Fagiolini, Andrea, Geddes, John R., Hajek, Tomas, Henry, Chantal, Kupka, Ralph, Lagerberg, Trine V., Licht, Rasmus W., Martinez-Cengotitabengoa, Monica, Morken, Gunnar, Nielsen, René E., Pinto, Ana Gonzalez, Reif, Andreas, Rietschel, Marcella, Ritter, Phillip, Schulze, Thomas G., Scott, Jan, Severus, Emanuel, Yildiz, Aysegul, Kessing, Lars Vedel, Bauer, Michael, Goodwin, Guy M., and Andreassen, Ole A.

Published
2020
Full Text
View/download PDF

34. Comorbid physical health burden of serious mental health disorders in 32 European countries

Author

Wienand, Dennis, Wijnen, Lena I., Heilig, Daniel, Wippel, Christoph, Arango, Celso, Knudsen, Gitte M., Goodwin, Guy M., Simon, Judit, Wienand, Dennis, Wijnen, Lena I., Heilig, Daniel, Wippel, Christoph, Arango, Celso, Knudsen, Gitte M., Goodwin, Guy M., and Simon, Judit

Abstract

Background Mental health disorders (MHDs) are associated with physical health disparities, but underlying excess risk and health burden have not yet been comprehensively assessed. Objective To assess the burden of comorbid physical health conditions (PHCs) across serious MHDs in Europe. Methods We estimated the relative prevalence risk of PHCs associated with alcohol use disorders (AUD), bipolar disorder (BD), depressive disorders (DD) and schizophrenia (SZ) across working-age populations of 32 European countries in 2019 based on a targeted literature review. Excess physical health burden was modelled using population-attributable fractions and country-level prevalence data. Findings We screened 10 960 studies, of which 41 were deemed eligible, with a total sample size of over 18 million persons. Relative prevalence of PHCs was reported in 54%, 20%, 15%, 5% and 7% of studies, respectively, for SZ, DD, BD, AUD or mixed. Significant relative risk estimates ranged from 1.44 to 3.66 for BD, from 1.43 to 2.21 for DD, from 0.81 to 1.97 for SZ and 3.31 for AUD. Excess physical health burden ranged between 27% and 67% of the total, corresponding to 84 million (AUD), 67 million (BD), 66 million (DD) and 5 million (SZ) PHC diagnoses in Europe. A 1% reduction in excess risk assuming causal inference could result in two million fewer PHCs across investigated MHDs. Conclusions This is the first comprehensive study of the physical health burden of serious MHDs in Europe. The methods allow for updates, refinement and extension to other MHDs or geographical areas. Clinical implications The results indicate potential population health benefits achievable through more integrated mental and physical healthcare and prevention approaches., BACKGROUND: Mental health disorders (MHDs) are associated with physical health disparities, but underlying excess risk and health burden have not yet been comprehensively assessed. OBJECTIVE: To assess the burden of comorbid physical health conditions (PHCs) across serious MHDs in Europe. METHODS: We estimated the relative prevalence risk of PHCs associated with alcohol use disorders (AUD), bipolar disorder (BD), depressive disorders (DD) and schizophrenia (SZ) across working-age populations of 32 European countries in 2019 based on a targeted literature review. Excess physical health burden was modelled using population-attributable fractions and country-level prevalence data. FINDINGS: We screened 10 960 studies, of which 41 were deemed eligible, with a total sample size of over 18 million persons. Relative prevalence of PHCs was reported in 54%, 20%, 15%, 5% and 7% of studies, respectively, for SZ, DD, BD, AUD or mixed. Significant relative risk estimates ranged from 1.44 to 3.66 for BD, from 1.43 to 2.21 for DD, from 0.81 to 1.97 for SZ and 3.31 for AUD. Excess physical health burden ranged between 27% and 67% of the total, corresponding to 84 million (AUD), 67 million (BD), 66 million (DD) and 5 million (SZ) PHC diagnoses in Europe. A 1% reduction in excess risk assuming causal inference could result in two million fewer PHCs across investigated MHDs. CONCLUSIONS: This is the first comprehensive study of the physical health burden of serious MHDs in Europe. The methods allow for updates, refinement and extension to other MHDs or geographical areas. CLINICAL IMPLICATIONS: The results indicate potential population health benefits achievable through more integrated mental and physical healthcare and prevention approaches.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results